Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers

A Single-Centre, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 Following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers

The study is carried out in order to investigate safety, tolerability and pharmacokinetics after administrating single and fractionated doses of AZD3241 to healthy volunteers

Inclusion Criteria:

• Provision of informed consent
• Body Mass Index (BMI) 19 to 30 kg/m2 inclusive
• Clinically normal physical findings, including BP, pulse rate, ECG and laboratory findings, as judged by the investigator

Exclusion Criteria:

• Clinically significant illness within the 2 weeks prior to the administration of the investigational product
• Heart rate (resting, recumbent) <50 bmp or >85 bmp
• History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity as judged by the investigator